Tag: Biogen Idec

Finance

Trending Stocks: Biogen Idec (NASDAQ:BIIB), The Procter & Gamble (NYSE:PG), Epizyme Inc (NASDAQ:EPZM), Johnson & Johnson (NYSE:JNJ)

Biogen Idec Inc. (NASDAQ:BIIB) announced it will report first quarter 2014 financial results on Wednesday, April 23, 2014, before the financial markets open. Biogen Idec Inc (NASDAQ:BIIB) stock performance was 1.28% in last session and finished the day at $309.79. Traded volume was 1.71million shares in the last session and the average volume of the stock remained 1.63million shares. The beta of the stock remained … Continue reading Trending Stocks: Biogen Idec (NASDAQ:BIIB), The Procter & Gamble (NYSE:PG), Epizyme Inc (NASDAQ:EPZM), Johnson & Johnson (NYSE:JNJ)

Jason Knox
Finance

Biotech Losers: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Novavax, Inc. (NASDAQ:NVAX), Biogen Idec Inc (NASDAQ:BIIB)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and AstraZeneca (NYSE:AZN) are among those companies with late stage drugs in trials that specifically target genetic mutations. Both BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s BMN-673, which is in phase 3 trials, and Astra’s Olaparib, which may get the EU’s go-ahead in ovarian cancer this year, address a mutation of the BRCA 1 and BRCA 2 gene that is often associated with breast … Continue reading Biotech Losers: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Novavax, Inc. (NASDAQ:NVAX), Biogen Idec Inc (NASDAQ:BIIB)

Jayne Crisman